• Harrow, Inc. has reported its past second-quarter 2026 results, with sales rising to US$70.66 million from US$63.74 million a year earlier, while moving from net income of US$5.00 million to a net loss of US$17.27 million.
• Over the first six months of 2026, sales inched up to US$114.86 million, but the company’s net loss deepened to US$44.87 million, sharply widening its loss per share from continuing operations.
• We’ll now examine how Harrow’s shift from profit to loss, despite higher sales, affects the previously outlined investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Harrow Investment Narrative Recap

To own Harrow, you have to believe its expanding ophthalmic portfolio can eventually support sustainable profitability, despite today’s deepening losses. The latest results do not appear to change the near term catalyst around execution on key brands, but they do sharpen the immediate risk that higher operating costs and heavier investment could keep Harrow in the red for longer than some investors might be comfortable with.

Among recent announcements, the July partnership update around BYOOVIZ stands out beside these results. Harrow is taking on commercialization of this ranibizumab biosimilar in the U.S., which ties directly into the investment case that future volume from biosimilars and retina products could help absorb today’s elevated costs. How quickly this new portfolio meaningfully contributes will be important for reassessing the balance between Harrow’s near term losses and its longer term opportunity.

But against that potential, investors should still be aware of the growing pressure from Harrow’s rising operating costs and deepening net losses...

Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029. This requires 42.9% yearly revenue growth and a $261.0 million earnings increase from -$15.0 million today.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Harrow could reach about US$866 million in revenue and US$263 million in earnings by 2029, which is a far more upbeat story than consensus, and your view on whether these Q2 losses reflect temporary growing pains or a more persistent cost problem will likely shape how comfortable you feel with that kind of optimism.

Explore 3 other fair value estimates on Harrow - why the stock might be worth over 8x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

No Opportunity In Harrow?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.